Literature DB >> 8612227

Local adenoviral-mediated expression of recombinant hirudin reduces neointima formation after arterial injury.

J J Rade1, A H Schulick, R Virmani, D A Dichek.   

Abstract

Catalytically active thrombin, acting locally, is thought to mediate neointima formation after arterial injury. We constructed an adenovirus vector, AdHV-1.2, containing a complementary DNA for the thrombin inhibitor hirudin. AdHV-1.2 directed the synthesis and secretion of biologically active hirudin from vascular cells in vitro. In vivo gene transfer of hirudin into smooth muscle cells of injured rat carotid arteries resulted in peak secretion of at least 34+/-23 pg hirudin per vessel per 24 hours, and resulted in a significant (P<0.05) 35% reduction in neointima formation. Systemic partial thromboplastin times were not affected by local hirudin expression. These results support the hypothesis that local thrombin activity contributes to neointima formation after arterial injury and suggest that local delivery of a highly specific antithrombin may constitute an effective intervention for arterial proliferative disease.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8612227     DOI: 10.1038/nm0396-293

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  20 in total

Review 1.  Gene therapy for vein graft disease.

Authors:  D G Cable; H V Schaff
Journal:  Curr Cardiol Rep       Date:  2001-01       Impact factor: 2.931

Review 2.  Clinical applications of vascular gene therapy.

Authors:  J Rutanen; T T Rissanen; A Kivelä; I Vajanto; S Ylä-Herttuala
Journal:  Curr Cardiol Rep       Date:  2001-01       Impact factor: 2.931

Review 3.  New developments in endovascular interventions for extracranial carotid stenosis.

Authors:  W A Tan; C R Jarmolowski; L R Wechsler; M H Wholey
Journal:  Tex Heart Inst J       Date:  2000

Review 4.  Antithrombotic strategies in gene therapy.

Authors:  K M Channon; B H Annex
Journal:  Curr Cardiol Rep       Date:  2000-01       Impact factor: 2.931

5.  Local gene transfer of tissue factor pathway inhibitor regulates intimal hyperplasia in atherosclerotic arteries.

Authors:  P Zoldhelyi; Z Q Chen; H S Shelat; J M McNatt; J T Willerson
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-27       Impact factor: 11.205

6.  Viral vectors for vascular gene therapy.

Authors:  Lukas Fischer; Meir Preis; Anat Weisz; Belly Koren; Basil S Lewis; Moshe Y Flugelman
Journal:  Exp Clin Cardiol       Date:  2002

Review 7.  Gene transfer to the vasculature: historical perspective and implication for future research objectives.

Authors:  Sarah J George; Andrew H Baker
Journal:  Mol Biotechnol       Date:  2002-10       Impact factor: 2.695

Review 8.  Gene therapy for restenosis: current status.

Authors:  Juha Rutanen; Johanna Markkanen; Seppo Ylä-Herttuala
Journal:  Drugs       Date:  2002       Impact factor: 9.546

9.  A role for Gab1/SHP2 in thrombin activation of PAK1: gene transfer of kinase-dead PAK1 inhibits injury-induced restenosis.

Authors:  Dong Wang; Biman C Paria; Qiuhua Zhang; Manjula Karpurapu; Quanyi Li; William T Gerthoffer; Yoshikazu Nakaoka; Gadiparthi N Rao
Journal:  Circ Res       Date:  2009-04-09       Impact factor: 17.367

Review 10.  Gene therapy for cerebral vascular disease: update 2003.

Authors:  Kazunori Toyoda; Yi Chu; Donald D Heistad
Journal:  Br J Pharmacol       Date:  2003-05       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.